Synthiko Formulations & Pharma Profile
Key Indicators
- Authorised Capital ₹ 3.00 M
- Paid Up Capital ₹ 3.00 M
- Company Age 17 Year, 11 Months
- Last Filing with ROC 31 Mar 2020
- Open Charges ₹ 1.48 Cr
- Revenue Growth -53.69%
- Profit Growth 16.83%
- Ebitda 41.30%
- Net Worth -176.13%
- Total Assets -3.68%
About Synthiko Formulations & Pharma
Synthiko Formulations & Pharma Private Limited (SFPPL) is a Private Limited Indian Non-Government Company incorporated in India on 12 March 2007 and has a history of 17 years and 11 months. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 3.00 M and a paid-up capital of Rs 3.00 M.
The company currently has active open charges totaling ₹1.48 Cr.
Mahesh Dadhia and Poonam Gupta serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24233MH2007PTC168635
- Company No.
168635
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Mar 2007
- Date of AGM
30 Dec 2020
- Date of Balance Sheet
31 Mar 2020
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Synthiko Formulations & Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mahesh Dadhia  | Director | 12-Mar-2007 | Current |
| Poonam Gupta | Director | 29-Sep-2018 | Current |
Financial Performance of Synthiko Formulations & Pharma.
Synthiko Formulations & Pharma Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 53.69% decrease. The company also saw a substantial improvement in profitability, with a 16.83% increase in profit. The company's net worth observed a substantial decline by a decrease of 176.13%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Synthiko Formulations & Pharma?
In 2019, Synthiko Formulations & Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹14.80 M
₹0
Charges Breakdown by Lending Institutions
- Indian Overseas Bank : 0.95 Cr
- Others : 0.53 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 01 Feb 2019 | Others | ₹5.30 M | Open |
| 02 Jun 2012 | Indian Overseas Bank | ₹9.50 M | Open |
How Many Employees Work at Synthiko Formulations & Pharma?
Unlock and access historical data on people associated with Synthiko Formulations & Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Synthiko Formulations & Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Synthiko Formulations & Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
